Atara Biotherapeutics (ATRA) EBITDA (2013 - 2026)

Atara Biotherapeutics has reported EBITDA for 14 years, with the latest figure at -$4.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 110.91% year-over-year to -$4.1 million; the trailing twelve-month figure through Mar 2026 stood at -$9.5 million (up 39.26% YoY), and the FY2025 full-year result was $32.7 million, up 138.36% from the prior year.
• EBITDA for Q1 2026 stood at -$4.1 million, down from -$3.4 million in the prior quarter.
• The five-year high for EBITDA was $38.0 million in Q1 2025, with the low at -$89.6 million in Q1 2022.
• Historically, EBITDA has averaged -$33.0 million across 5 years, with a median of -$21.9 million in 2024.
• Annual changes were most pronounced in 2023 — EBITDA sank 499.12% — and 2025, when it jumped 220.25%.
• Atara Biotherapeutics' EBITDA stood at -$73.7 million in 2022, then grew by 18.45% to -$60.1 million in 2023, then jumped by 78.85% to -$12.7 million in 2024, then surged by 73.19% to -$3.4 million in 2025, then retreated by 21.69% to -$4.1 million in 2026.
• The last three EBITDA figures came in at -$4.1 million (Q1 2026), -$3.4 million (Q4 2025), and -$4.3 million (Q3 2025), per Business Quant data.